Analyzing Grace Therapeutics (GRCE) and The Competition

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Grace Therapeutics to similar companies based on the strength of its dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Grace Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Valuation and Earnings

This table compares Grace Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.71
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-5.71

Grace Therapeutics’ rivals have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Grace Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ rivals have a beta of 3.84, meaning that their average share price is 284% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Grace Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8451	22315	50512	1356	2.54

Grace Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 506.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 245.64%. Given Grace Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Grace Therapeutics beats its rivals on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.